Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. - Wikidata - awgldk - TriplyDB

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

http://www.wikidata.org/entity/Q37541469

about

CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.Lupus nephritis and B-cell targeting therapy.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Disentangling the role of neutrophil extracellular traps in rheumatic diseases.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Neutrophil-mediated vascular barrier injury: Role of neutrophil extracellular traps.The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Unraveling Vascular Inflammation: From Immunology to Imaging.Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Overexpression of microRNA-506-3p aggravates the injury of vascular endothelial cells in patients with hypertension by downregulating Beclin1 expression.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases.Polydatin effectively attenuates disease activity in lupus-prone mouse models by blocking ROS-mediated NET formation

P2860

Q37730623-3434A914-6A01-4CE4-830A-475F811FA0C6 Q38643755-3CD4C246-2479-41AE-859B-4D44416DDB2E Q38751230-8EFD930F-5076-41DE-86AB-7086E621BF14 Q38984163-7DB38169-C74D-4145-B8B4-24FC439C2339 Q39039141-F529B94F-8A21-4FCC-94AD-3F598C016929 Q39102339-413ADDA1-2276-40F5-A23F-55B6D379BB97 Q39388632-BB43CFA9-B7B3-4892-A0AE-3E11C4A79051 Q39413866-BC29310B-76E3-45E4-B578-192638F6B640 Q41363502-9A2A34B7-BEC7-4E6E-BC56-C2B87C8B2BD5 Q47439880-9922471F-37B4-498D-AC75-5CD1A1C156F0 Q47960412-96A6129E-BA15-466F-BE23-569DE4651D6F Q48227295-4992F20F-7C8B-4A78-91BF-6342A822840C Q48556502-87FA2E43-29D9-4CED-BE31-A1EA864BDC07 Q49875499-FBC323AD-9068-4352-8331-560490EDDC5B Q50068095-B2979C0B-F05C-4947-B384-881F6516F95F Q52343466-A8BE680B-CADA-433F-B90D-92ED06B657E6 Q55163735-43116F2C-9083-4515-8722-751E07EB0A80 Q55383884-7597985F-3F8D-4176-954C-16674295AE1D Q59136119-9073422D-64A2-4B52-BE95-7EA735D256B6

P2860

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

http://www.wikidata.org/entity/Q37541469

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@en

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@nl

type

label

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@en

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@nl

prefLabel

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@en

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

@nl

P1433

Q37541469-4E183B61-2576-47BD-9C61-81F724F78C00

P1476

Q37541469-01F6638A-9825-435A-90F7-99CCA011312E

P2093

Q37541469-2E2DE308-84AC-478E-95EB-5769DF5503D5

Q37541469-3961F736-7882-4DB6-9FF8-1C80CC2F080A

Q37541469-430A6A48-230D-472D-A307-CCDEF24E482E

Q37541469-612BE457-0705-4C33-AC1E-9CC3179698AA

Q37541469-8456A565-D398-422E-AB24-EF175D7B9505

Q37541469-8519D6AB-7DC4-434F-B4D1-7549E285C272

Q37541469-9655B81D-9640-4652-8491-61B6F4F697AC

Q37541469-99286AEA-0537-436E-8730-0F6635D3240F

Q37541469-9C939425-7B7D-4F4A-8404-57F33DAE8321

Q37541469-B9A77F4F-8EA7-4B59-BE0D-FB70120B09F9

P2860

Q37541469-019BF341-B6E3-4114-99E7-7B87361DC708

Q37541469-07D1D891-96E5-43EA-92FF-D2EE7C065E6D

Q37541469-09F58484-6B9E-4F9B-8DFA-F788D2190EF7

Q37541469-0D1A8999-D831-410F-BCA9-B3EDBB5C3DDB

Q37541469-0E7B7513-4869-482D-93B6-933E86DC026C

Q37541469-12F75263-8B36-4483-ACB7-0FAA4ACB9819

Q37541469-14E55064-FDEE-409C-8B05-70E231ACE348

Q37541469-15618FA5-7F1F-49A8-92C4-25452FBEC7EA

Q37541469-1A98FD20-3658-48C7-92C2-E680075B5CE3

Q37541469-24003958-6CD5-4B57-A455-F1AAD6D0EF5D

P304

Q37541469-FC057496-9856-4780-81A2-4310E051BFF1

P31

Q37541469-7FE602EB-A44F-4061-91C8-2A723621D913

P356

Q37541469-781FF5AA-D6A9-4042-ADDB-52ED66030528

P433

Q37541469-ECD99A5B-7B3E-4569-B38A-3D53935B1690

P478

Q37541469-1A69CFF9-F610-44C7-A617-EBAFC2341292

P50

Q37541469-0D1D1BD0-F6FA-4B9F-9798-E13E0CCE8566

Q37541469-961EC5A0-1C58-4246-B87E-8ECF5A0398E1

Q37541469-E8A1A10E-BA3A-46D3-91EB-A4B0E09B97A1

P577

Q37541469-A4EE33AD-186D-4767-BF70-3A63706E5C59

P698

Q37541469-CFD3C579-BA29-4EFF-9315-E8FE47DEE406

P932

Q37541469-105A1A1F-BCAD-4AD2-9FE5-FBD1DECF6C30

P356

P1433

Arthritis & Rheumatology

P1476

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

@en

P2093

Alan T Remaley

http://www.w3.org/2001/XMLSchema#string

Carolyne K Smith

http://www.w3.org/2001/XMLSchema#string

John J O'Shea

http://www.w3.org/2001/XMLSchema#string

Laurel Mast

http://www.w3.org/2001/XMLSchema#string

Leti Nunez

http://www.w3.org/2001/XMLSchema#string

Mariana J Kaplan

http://www.w3.org/2001/XMLSchema#string

Massimo Gadina

http://www.w3.org/2001/XMLSchema#string

Seth G Thacker

http://www.w3.org/2001/XMLSchema#string

Stephen R Brooks

http://www.w3.org/2001/XMLSchema#string

Victoria Hoffmann

http://www.w3.org/2001/XMLSchema#string

P2860

Neutrophils in the pathogenesis and manifestations of SLE

The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells

Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare

A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus

The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.

P304

148-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39818

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Sciumé

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27429362

http://www.w3.org/2001/XMLSchema#string

P932

5195893

http://www.w3.org/2001/XMLSchema#string